The third quarter of 2022 saw progress in several areas, such as the construction of the laboratory facilities in Campus Solna in Stockholm, the setup of a simulation laboratory in Linköping and the recruitment of skilled personnel, including that of Dr. Claes Lindh, the company’s new Chief Medical Officer (CMO) as of September. Some highlights of […]
STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on track in building its first ultramodern laboratory at Campus Solna, Sweden, next to world-leading healthcare. “We signed a five-year leasing contract for our office and […]
STOCKHOLM – May 30th, 2022 Inify Laboratories AB has decided to extend the Subscription Period in the ongoing Subsequent Offering to 3 June 2022 at 16:30 hours (CEST). As a consequence of this extension, the payment date will be on or about 8 June 2022 and delivery of shares will take place on or about […]
STOCKHOLM – 9 maj 2022 Inify Laboratories har hållit en extra bolagsstämma den 9 maj 2022. Bifogat finns en sammanfattning av de beslut som fattades vid den extra bolagsstämman. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Sammanfattning Extra bolagsstämma 2022-05-09 (pdf)
STOCKHOLM – 11 april 2022 Inify Laboratories bjuder härmed in sina aktieägare till en extra bolagsstämma den 9 maj 2022. Bifogat finns kallelse inklusive dagordning och information om hur man registrerar sig och röstar. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Kallelse extra bolagsstämma (pdf) Anmälningsblankett bolagsstämma (pdf) Styrelsens redogörelse enligt 13 […]
STOCKHOLM – December 10, 2021 – ContextVision, a medical technology software company specializing in image processing, today announces that at the EGM of ContextVision on Dec 10th, it was resolved that the subsidiary INIFY Laboratories will become an independent company through a distribution of its shares to existing shareholders of ContextVision. The company will build […]
ContextVision today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.
ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.
INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers
ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.
In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites
STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]